CLL
From the Journals
CLL and surgery are more compatible than ever
As patients fare better with targeted therapy, physicians say they can tolerate more procedures.
From the Journals
Erythema extent predicts death in cutaneous GVHD
Study: Extent of skin erythema correlates with deaths from graft-versus-host disease in blood cancer patients after stem cell transplants.
From the Journals
Venetoclax shows promise for r/r hairy cell leukemia
Italian study suggests benefits of administering venetoclax for patients with r/r cases of hairy cell leukemia, a rare blood cancer,
From the Journals
CLL treatment: More infections among real-world patients
Among real-world blood cancer patients treated with three drugs, study finds higher infection rates than in clinical trials.
From the Journals
Surviving CLL: Higher risk of other cancer DXs
A 30-year Dutch population study highlights the medical challenges facing patients with CLL, who are now living longer.
From the Journals
Despite limits, COVID vaccines protect CLL patients
A small German study found that, in patients with CLL, COVID-19 shots don’t boost B cells but they do strengthen T cells.
From the Journals
Adding venetoclax improves ibrutinib outcomes in CLL
A small study yields sanguine news about a combination treatment, as hematologists await phase 3 results.
News
FDA OKs zanubrutinib for CLL or SLL
Zanubrutinib for treatment of chronic lymphocytic leukemia or small lymphocytic lymphoma has been greenlighted by the FDA.
Conference Coverage
CLL phase 3 study: Zanubrutinib bests ibrutinib
The second-generation Bruton’s tyrosine kinase inhibitor zanubrutinib outperformed ibrutinib in a phase 3 study.
Feature
High cost and demand for old cancer drug sparks crisis
Experts have voiced alarm at the scarcity and cost of fludarabine, an old drug deemed crucial to cellular therapy for leukemia.
News
FDA approved acalabrutinib tablet for MCL, CLL, SLL
Acalabrutinib (Calquence) in tablet formulation approved by FDA.